Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
J Transl Med. 2009 Dec 18;7:108. doi: 10.1186/1479-5876-7-108.
HIV and HPV can both cause chronic infections and are acquired during sexual contact. HIV infection results in a progressive loss of CD4+ T cells that is associated with an increased prevalence of HPV infections, type-specific persistence and an increase in HPV-associated malignancies. On the one hand this illustrates the important role of HPV-specific CD4+ helper T-cell immunity, on the other it shows the Achilles heel of the HPV-specific immune response. The use of highly active antiretroviral therapy (HAART) results in a rapid reduction of HIV and a reconstitution of systemic CD4+ T-cell levels. The use of HAART thus has the potential to raise immunity to HPV but to the surprise of many, the incidence of HPV-induced diseases has increased rather than declined since the introduction of HAART. Here, the knowledge on how HPV-induced diseases develop in the face of a non-compromised immune system will be used to explain why the effect of HAART on HPV-induced diseases is modest at best. Furthermore, exciting new data in the field of therapeutic vaccines against HPV will be discussed as this may form a more durable and clinically successful therapeutic approach for the treatment of HPV-induced high-grade lesions in HIV-positive subjects on HAART.
HIV 和 HPV 均可导致慢性感染,且可通过性接触传播。HIV 感染会导致 CD4+T 细胞逐渐减少,从而增加 HPV 感染、特定类型持续性和 HPV 相关恶性肿瘤的发生率。一方面,这说明了 HPV 特异性 CD4+辅助性 T 细胞免疫的重要作用;另一方面,也说明了 HPV 特异性免疫应答的弱点。高效抗逆转录病毒疗法(HAART)的应用可迅速降低 HIV 载量并重建全身 CD4+T 细胞水平。因此,HAART 有可能提高对 HPV 的免疫力,但令许多人惊讶的是,自从 HAART 问世以来,HPV 引起的疾病的发病率不仅没有下降反而上升了。在这里,我们将利用关于在免疫系统未受损的情况下 HPV 诱导疾病如何发展的知识,来解释为什么 HAART 对 HPV 诱导疾病的影响充其量只是适度的。此外,我们还将讨论 HPV 治疗性疫苗领域令人兴奋的新数据,因为这可能为治疗接受 HAART 的 HIV 阳性者的 HPV 诱导的高级别病变提供更持久和更成功的治疗方法。